NO985197L - Reparasjon og forebygging av fibrotiske lesjoner - Google Patents
Reparasjon og forebygging av fibrotiske lesjonerInfo
- Publication number
- NO985197L NO985197L NO985197A NO985197A NO985197L NO 985197 L NO985197 L NO 985197L NO 985197 A NO985197 A NO 985197A NO 985197 A NO985197 A NO 985197A NO 985197 L NO985197 L NO 985197L
- Authority
- NO
- Norway
- Prior art keywords
- repair
- prevention
- fibrotic lesions
- pyridones
- substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/647,006 US5716632A (en) | 1989-11-22 | 1996-05-09 | Compositions and methods for reparation and prevention of fibrotic lesions |
PCT/US1997/007468 WO1997041830A1 (fr) | 1996-05-09 | 1997-05-03 | Reparation et prevention des lesions fibreuses |
Publications (2)
Publication Number | Publication Date |
---|---|
NO985197L true NO985197L (no) | 1998-11-06 |
NO985197D0 NO985197D0 (no) | 1998-11-06 |
Family
ID=24595333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO985197A NO985197D0 (no) | 1996-05-09 | 1998-11-06 | Reparasjon og forebygging av fibrotiske lesjoner |
Country Status (11)
Country | Link |
---|---|
US (1) | US5716632A (fr) |
EP (1) | EP0902680A4 (fr) |
JP (1) | JP2000510467A (fr) |
KR (1) | KR20000010676A (fr) |
AU (1) | AU725637B2 (fr) |
CA (1) | CA2253919A1 (fr) |
IL (1) | IL126891A0 (fr) |
NO (1) | NO985197D0 (fr) |
TR (1) | TR199802273T2 (fr) |
WO (1) | WO1997041830A1 (fr) |
ZA (1) | ZA974041B (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
EP1069898B1 (fr) * | 1998-03-17 | 2004-05-12 | MARGOLIN, Solomon B. | Compositions et methodes topiques antiseptiques |
JP2002526447A (ja) | 1998-09-18 | 2002-08-20 | メファ・アクチェンゲゼルシャフト | アルキルフェニルピリドンの局所製剤 |
CA2388840C (fr) * | 2000-01-24 | 2011-09-13 | Solomon B. Margolin | Traitement de lymphomes, de leucemies, de carcinomes mammaires, d'astrocytomes, de melanomes, de leiomyomes et de tumeurs apparentees |
DE10053870A1 (de) * | 2000-10-31 | 2002-05-08 | Burchardt Elmar Reinhold | Procollagen (III)-Propeptide und verwandte Substanzen zur Behandlung von fibrotischen Erkrankungen |
US7867516B2 (en) * | 2001-01-29 | 2011-01-11 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
US20060110358A1 (en) * | 2002-08-28 | 2006-05-25 | Hsu Henry H | Combination therapy for treatment of fibrotic disorders |
TW200418516A (en) * | 2003-02-21 | 2004-10-01 | Shionogi & Co | Droplet dispersed ointment |
US20070072181A1 (en) * | 2003-02-28 | 2007-03-29 | Blatt Lawrence M | Combination therapy for treating alphavirus infection and liver fibrosis |
US20070092488A1 (en) * | 2003-05-16 | 2007-04-26 | Intermune Inc. | Methods of treating idiopathic pulmonary fibrosis |
EP1633317A4 (fr) | 2003-05-16 | 2008-08-20 | Intermune Inc | Ligands des recepteurs des chimiokines synthetiques et leurs methodes d'utilisation |
AP2287A (en) | 2003-10-14 | 2011-10-31 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
WO2005040758A2 (fr) * | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Utilisation de pirfenidone dans des posologies therapeutiques |
JP4614884B2 (ja) * | 2003-11-14 | 2011-01-19 | シャンハイ ゲノミックス インク | ピリドンの誘導体とその使用 |
JP2008513356A (ja) * | 2004-08-09 | 2008-05-01 | アリオス バイオファーマ インク. | 合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法 |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
CN1846699A (zh) | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | 1-(取代苯基)-5-甲基-2-(1h) 吡啶酮(i)化合物用于制备抗除肾间质纤维化外其他器官纤维化或组织纤维化药物的应用 |
KR20080023680A (ko) * | 2005-05-10 | 2008-03-14 | 인터뮨, 인크. | 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체 |
EP2305695A3 (fr) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C |
NZ591443A (en) | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
CN101415705B (zh) | 2005-10-11 | 2011-10-26 | 因特蒙公司 | 抑制丙型肝炎病毒复制的化合物和方法 |
CN101304976A (zh) * | 2005-10-11 | 2008-11-12 | 因特蒙公司 | 病毒复制抑制剂 |
CN101460476B (zh) * | 2006-06-05 | 2013-12-04 | 诺瓦提斯公司 | 有机化合物 |
RU2008152171A (ru) * | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
AU2008216382A1 (en) * | 2007-02-12 | 2008-08-21 | Array Biopharma, Inc. | Novel inhibitors hepatitis C virus replication |
CN101472588A (zh) * | 2007-04-27 | 2009-07-01 | 达瑞科技投资有限公司 | 5-甲基-1-(取代苯基)-2-(1H)吡啶酮化合物作为抗炎药物和α-肿瘤坏死因子(TNF-α)阻断剂的应用 |
US20090155209A1 (en) | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
EP2185524A1 (fr) * | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Nouveaux inhibiteurs peptidiques de la réplication du virus de l'hépatite c |
MX2007009796A (es) * | 2007-08-14 | 2009-02-25 | Cell Therapy And Technology S | Gel conteniendo pirfenidona. |
US9029385B2 (en) * | 2007-10-26 | 2015-05-12 | Ganesh Raghu | Compositions and methods for treating fibroproliferative disorders |
EP2262501B1 (fr) * | 2008-03-07 | 2014-08-13 | Solanan, Inc. | Traitement d' une septicémie avec 5-éthyl-1-phényl-2(1h)-pyridone |
MX2010012848A (es) | 2008-06-03 | 2011-03-01 | Intermune Inc | Compuestos y metodos para tratar trastornos inflamatorios y fibroticos. |
AP2011005695A0 (en) | 2008-10-15 | 2011-06-30 | Intermune Inc | Therapeutic antiviral poptides. |
US7566729B1 (en) | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
US7635707B1 (en) | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
AU2010206543A1 (en) * | 2009-01-26 | 2011-07-07 | Intermune, Inc. | Methods for treating acute myocardial infarctions and associated disorders |
WO2010135972A1 (fr) | 2009-05-25 | 2010-12-02 | 中南大学 | Procédés de préparation et utilisations de composés de 1-(aryl substitué)-5-trifluorométhyl-2-(1h)-pyridone et de leurs sels |
ES2536200T3 (es) | 2009-05-25 | 2015-05-21 | Central South University | Preparación de compuestos de tipo 1-(bencilo sustituido)-5-trifluorometil-2-(1H)piridona, sales de estos y sus aplicaciones |
MX2012003500A (es) | 2009-09-28 | 2012-08-01 | Intermune Inc | Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c. |
WO2011054893A2 (fr) | 2009-11-05 | 2011-05-12 | Novartis Ag | Marqueurs biologiques prédictifs de l'évolution d'une fibrose |
US7816383B1 (en) | 2009-12-04 | 2010-10-19 | Intermune, Inc. | Methods of administering pirfenidone therapy |
US8084475B2 (en) | 2009-12-04 | 2011-12-27 | Intermune, Inc. | Pirfenidone therapy and inducers of cytochrome P450 |
DK2670242T3 (da) * | 2011-01-31 | 2022-05-02 | Avalyn Pharma Inc | Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
WO2012107831A1 (fr) | 2011-02-11 | 2012-08-16 | Signa S.A. De C.V. | Procédé de fabrication d'un composé de pyridone, 5-éthyl-1-phényl-2-(1h)-pyridone, et ses intermédiaires |
CA2819967C (fr) | 2012-08-31 | 2016-03-22 | Intermune, Inc. | Utilisation de pirfenidone en simultanee avec du ciprofloxacin |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CA2936330C (fr) | 2014-01-10 | 2023-01-03 | Genoa Pharmaceuticals Inc. | Composes analogues de pyridone et de pirfenidone en aerosol, et leurs utilisations |
CN106459042B (zh) | 2014-04-02 | 2019-06-28 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
CA2937365C (fr) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee |
EP3612215A4 (fr) * | 2017-04-20 | 2021-05-26 | aTyr Pharma, Inc. | Compositions et procédés pour le traitement d'inflammation pulmonaire |
CN114716365B (zh) * | 2022-01-04 | 2024-03-01 | 大连理工大学 | 一类n-取代苯基-2-吡啶酮化合物或其可药用盐在治疗肺纤维化中的应用 |
CN114805333A (zh) * | 2022-05-09 | 2022-07-29 | 大连理工大学 | 一种主链含噁嗪和Cardo结构的双马来酰亚胺及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1049411A (fr) * | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | Pyridone n-substituee; methode generale de synthese des pyridones |
JPH02215719A (ja) * | 1989-02-15 | 1990-08-28 | Yamauchi Akitomo | 線維化病変組織の修復並びに線維化病変の阻止剤 |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5518729A (en) * | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
CA2161648A1 (fr) * | 1993-05-07 | 1994-11-24 | Solomon B. Margolin | Compositions et methodes pour la preparation et la prevention de lesions fibreuses |
US5789426A (en) * | 1995-01-20 | 1998-08-04 | Cornell Research Foundation, Inc. | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation |
ATE265851T1 (de) * | 1995-03-03 | 2004-05-15 | Solomon B Margolin | Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden |
AU709178B2 (en) * | 1995-09-19 | 1999-08-26 | Intermune, Inc. | Inhibition of tumor necrosis factor alpha |
-
1996
- 1996-05-09 US US08/647,006 patent/US5716632A/en not_active Expired - Lifetime
-
1997
- 1997-05-03 WO PCT/US1997/007468 patent/WO1997041830A1/fr not_active Application Discontinuation
- 1997-05-03 KR KR1019980708678A patent/KR20000010676A/ko not_active Application Discontinuation
- 1997-05-03 AU AU27519/97A patent/AU725637B2/en not_active Ceased
- 1997-05-03 TR TR1998/02273T patent/TR199802273T2/xx unknown
- 1997-05-03 IL IL12689197A patent/IL126891A0/xx unknown
- 1997-05-03 CA CA002253919A patent/CA2253919A1/fr not_active Abandoned
- 1997-05-03 EP EP97921495A patent/EP0902680A4/fr not_active Withdrawn
- 1997-05-03 JP JP09540064A patent/JP2000510467A/ja active Pending
- 1997-05-09 ZA ZA974041A patent/ZA974041B/xx unknown
-
1998
- 1998-11-06 NO NO985197A patent/NO985197D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0902680A4 (fr) | 2000-04-19 |
JP2000510467A (ja) | 2000-08-15 |
US5716632A (en) | 1998-02-10 |
ZA974041B (en) | 1998-11-09 |
NO985197D0 (no) | 1998-11-06 |
CA2253919A1 (fr) | 1997-11-13 |
TR199802273T2 (xx) | 2000-11-21 |
EP0902680A1 (fr) | 1999-03-24 |
KR20000010676A (ko) | 2000-02-25 |
WO1997041830A1 (fr) | 1997-11-13 |
IL126891A0 (en) | 1999-09-22 |
AU725637B2 (en) | 2000-10-19 |
AU2751997A (en) | 1997-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO985197L (no) | Reparasjon og forebygging av fibrotiske lesjoner | |
NO951613L (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
CY1115589T1 (el) | Φαρμακευτικες συνθεσεις για την προληψη και αγωγη των διαταραχων του κεντρικου νευρικου συστηματος περιλαμβανοντας μια νικοτινικη ενωση και εναν αναστολεα ακετυλχολινεστερασης | |
BR9908332A (pt) | Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia | |
ES2133270T3 (es) | Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna. | |
BR9406461A (pt) | Composições e métodos para a reparação e prevenção de les~es fibróticas | |
DE69837809D1 (de) | Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen | |
PT788481E (pt) | Processo para preparacao de levobupivacaina e seus analogos | |
YU48698A (sh) | Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze | |
EA199800721A1 (ru) | Ингибитор реваскуляризации | |
BR0017157A (pt) | Derivados de 6-hidroxi-indazol para o tratamento de glaucoma | |
DE69732709D1 (de) | Expressionsblockierung von virulenten faktoren in s. aureus | |
BR9612018A (pt) | Processos e intermediários para preparação de 1-benzil-4- ((5,6-dimetóxi-1-indanon)-2-il)metilpiperid ina | |
DK0810991T3 (da) | 1-Aryl-2-acylamino-ethan-forbindelser og deres anvendelse som neurokinin- især neurokinin-1-antagonister | |
WO2001087287A3 (fr) | Composes actifs sur le plan pharmaceutiques et procedes d'utilisation | |
MXPA02000330A (es) | Pirrolidinas y piperidinas neurotroficas y composiciones y metodos relacionados. | |
DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ES2171233T3 (es) | Uso de eliprodil para la preparacion de un medicamento para el tratamiento de trastornos isquemicos de la retina o el nervio optico. | |
AR020740A1 (es) | Composicion y metodo para tratar enfermedades alergicas | |
TR200003544T2 (tr) | Kas-iskelet zayıflığının tedavisine yönelik terapötik kombinasyonlar. | |
DE69731657D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
BR9714189A (pt) | N-(piridinilamino) isoindolinas e compostos relacionados | |
BG104604A (en) | Process for the preparation of paroxetin hydrochloride | |
RS20050690A (sr) | 2-(butil-1-sulfonilamino)-n-/1(r)-(6- metoksi-piridin-3-il)- propil/- benzamid, njegova primena u svojstvu leka kao i farmaceutski preparati koji sadrže ova jedinjenja | |
ATE308523T1 (de) | Ester von 3-(3,4-dihalogenophenyl)-2,6- dioxopiperidine-3-propionsäure als zwischenprodukte |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |